231 related articles for article (PubMed ID: 32218809)
21. FGFR2 Promotes Expression of PD-L1 in Colorectal Cancer via the JAK/STAT3 Signaling Pathway.
Li P; Huang T; Zou Q; Liu D; Wang Y; Tan X; Wei Y; Qiu H
J Immunol; 2019 May; 202(10):3065-3075. PubMed ID: 30979816
[TBL] [Abstract][Full Text] [Related]
22. Clinical significance of programmed cell death-ligand 1 expression and the immune microenvironment at the invasive front of colorectal cancers with high microsatellite instability.
Korehisa S; Oki E; Iimori M; Nakaji Y; Shimokawa M; Saeki H; Okano S; Oda Y; Maehara Y
Int J Cancer; 2018 Feb; 142(4):822-832. PubMed ID: 29044503
[TBL] [Abstract][Full Text] [Related]
23. The Role of Yes-Associated Protein (YAP) in Regulating Programmed Death-Ligand 1 (PD-L1) in Thoracic Cancer.
Hsu PC; Yang CT; Jablons DM; You L
Biomedicines; 2018 Dec; 6(4):. PubMed ID: 30544524
[TBL] [Abstract][Full Text] [Related]
24. Increased intratumoral mast cells foster immune suppression and gastric cancer progression through TNF-α-PD-L1 pathway.
Lv Y; Zhao Y; Wang X; Chen N; Mao F; Teng Y; Wang T; Peng L; Zhang J; Cheng P; Liu Y; Kong H; Chen W; Hao C; Han B; Ma Q; Zou Q; Chen J; Zhuang Y
J Immunother Cancer; 2019 Feb; 7(1):54. PubMed ID: 30808413
[TBL] [Abstract][Full Text] [Related]
25. BIN1 reverses PD-L1-mediated immune escape by inactivating the c-MYC and EGFR/MAPK signaling pathways in non-small cell lung cancer.
Wang J; Jia Y; Zhao S; Zhang X; Wang X; Han X; Wang Y; Ma M; Shi J; Liu L
Oncogene; 2017 Nov; 36(45):6235-6243. PubMed ID: 28714960
[TBL] [Abstract][Full Text] [Related]
26. The Interplay of Notch Signaling and STAT3 in TLR-Activated Human Primary Monocytes.
Hildebrand D; Uhle F; Sahin D; Krauser U; Weigand MA; Heeg K
Front Cell Infect Microbiol; 2018; 8():241. PubMed ID: 30042932
[TBL] [Abstract][Full Text] [Related]
27. Juxtacrine Signaling Inhibits Antitumor Immunity by Upregulating PD-L1 Expression.
Yang WH; Cha JH; Xia W; Lee HH; Chan LC; Wang YN; Hsu JL; Ren G; Hung MC
Cancer Res; 2018 Jul; 78(14):3761-3768. PubMed ID: 29789418
[TBL] [Abstract][Full Text] [Related]
28. Combination of Sunitinib and PD-L1 Blockade Enhances Anticancer Efficacy of TLR7/8 Agonist-Based Nanovaccine.
Kim H; Khanna V; Kucaba TA; Zhang W; Ferguson DM; Griffith TS; Panyam J
Mol Pharm; 2019 Mar; 16(3):1200-1210. PubMed ID: 30620878
[TBL] [Abstract][Full Text] [Related]
29. Programmed Cell Death Ligand 1 (PD-L1) Signaling Regulates Macrophage Proliferation and Activation.
Hartley GP; Chow L; Ammons DT; Wheat WH; Dow SW
Cancer Immunol Res; 2018 Oct; 6(10):1260-1273. PubMed ID: 30012633
[TBL] [Abstract][Full Text] [Related]
30. Analysis of the Expression and Regulation of PD-1 Protein on the Surface of Myeloid-Derived Suppressor Cells (MDSCs).
Nam S; Lee A; Lim J; Lim JS
Biomol Ther (Seoul); 2019 Jan; 27(1):63-70. PubMed ID: 30521746
[TBL] [Abstract][Full Text] [Related]
31. Radiotherapy Both Promotes and Inhibits Myeloid-Derived Suppressor Cell Function: Novel Strategies for Preventing the Tumor-Protective Effects of Radiotherapy.
Ostrand-Rosenberg S; Horn LA; Ciavattone NG
Front Oncol; 2019; 9():215. PubMed ID: 31001479
[TBL] [Abstract][Full Text] [Related]
32. Programmed cell death ligand 1 (PD-L1) expression is not a predominant feature in Ewing sarcomas.
Spurny C; Kailayangiri S; Jamitzky S; Altvater B; Wardelmann E; Dirksen U; Hardes J; Hartmann W; Rossig C
Pediatr Blood Cancer; 2018 Jan; 65(1):. PubMed ID: 28868758
[TBL] [Abstract][Full Text] [Related]
33. Inducible but not constitutive expression of PD-L1 in human melanoma cells is dependent on activation of NF-κB.
Gowrishankar K; Gunatilake D; Gallagher SJ; Tiffen J; Rizos H; Hersey P
PLoS One; 2015; 10(4):e0123410. PubMed ID: 25844720
[TBL] [Abstract][Full Text] [Related]
34. Extracellular Vesicles From Gastric Cancer Cells Induce PD-L1 Expression on Neutrophils to Suppress T-Cell Immunity.
Shi Y; Zhang J; Mao Z; Jiang H; Liu W; Shi H; Ji R; Xu W; Qian H; Zhang X
Front Oncol; 2020; 10():629. PubMed ID: 32477934
[TBL] [Abstract][Full Text] [Related]
35. Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1.
Wen ZF; Liu H; Gao R; Zhou M; Ma J; Zhang Y; Zhao J; Chen Y; Zhang T; Huang F; Pan N; Zhang J; Fox BA; Hu HM; Wang LX
J Immunother Cancer; 2018 Dec; 6(1):151. PubMed ID: 30563569
[TBL] [Abstract][Full Text] [Related]
36. Immunosuppression of Human Adipose-Derived Stem Cells on T Cell Subsets via the Reduction of NF-kappaB Activation Mediated by PD-L1/PD-1 and Gal-9/TIM-3 Pathways.
Zhou K; Guo S; Tong S; Sun Q; Li F; Zhang X; Qiao Y; Liang G
Stem Cells Dev; 2018 Sep; 27(17):1191-1202. PubMed ID: 29978730
[TBL] [Abstract][Full Text] [Related]
37. Application of PD-1 Blockade in Cancer Immunotherapy.
Wu X; Gu Z; Chen Y; Chen B; Chen W; Weng L; Liu X
Comput Struct Biotechnol J; 2019; 17():661-674. PubMed ID: 31205619
[TBL] [Abstract][Full Text] [Related]
38. Interleukin-22 promotes PD-L1 expression via STAT3 in colon cancer cells.
Xi X; Hu R; Wang Q; Xu K; Yang H; Cui Z; Zhang Y; Teng M; Xia L; Chen J; Liu Y
Oncol Lett; 2021 Oct; 22(4):716. PubMed ID: 34429756
[TBL] [Abstract][Full Text] [Related]
39. Integrin-Linked Kinase Expression Characterizes the Immunosuppressive Tumor Microenvironment in Colorectal Cancer and Regulates PD-L1 Expression and Immune Cell Cytotoxicity.
Almasabi S; Boyd R; Ahmed AU; Williams BRG
Front Oncol; 2022; 12():836005. PubMed ID: 35692780
[TBL] [Abstract][Full Text] [Related]
40. Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation.
Chen N; Fang W; Zhan J; Hong S; Tang Y; Kang S; Zhang Y; He X; Zhou T; Qin T; Huang Y; Yi X; Zhang L
J Thorac Oncol; 2015 Jun; 10(6):910-23. PubMed ID: 25658629
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
